Biotech News
-
Hemostemix Announces HS 12 – 01 Clinical Trial Completion of Subjects’ Follow-Up Visits at the End of March and Warrants Extended and Repriced
January 28, 2021 (Source) — Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (“Hemostemix” or the “Company”) is pleased to…
-
XPhyto Announces Drug Formulation Strategy and 2021 Milestones Innovation to Impact
January 28, 2021 (Source) — Construction of commercial drug manufacturing facility in Germany Four clinical studies in neurological…
-
Predictmedix Inc. – Corporate Update
January 25, 2021 (Source) — Predictmedix Inc. (CSE:PMED) (OTCQB:PMEDF) (“Predictmedix” or the “Company”) is pleased to provide a corporate update…
-
Valeo Pharma’s Redesca™ Receives Positive Recommendation for Public Reimbursement in Quebec
January 25, 2021 (Source) — Valeo Pharma Inc. (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) (“Valeo” or the “Company”),…
-
XPhyto Provides Comments on Promotional and Marketing Activity
January 22, 2021 (Source) — XPhyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT) (“XPhyto” or the “Corporation”) at the request of OTC Markets, is providing…
-
Hemostemix Announces the Bread Contract with the Department of Foreign Affairs, Trade & Development Canada
January 22, 2021 (Source) — Hemostemix Inc. (TSXV: HEM) (OTC: HMTXD) (“Hemostemix” or the “Company”) is pleased to announce…
-
DIAGNOS Successfully Completes ISO 13485 / MDSAP Audit
January 21, 2021 (Source) — Diagnos Inc. (“DIAGNOS”, the “Corporation” or ”we”) (TSX Venture: ADK) (OTCQB: DGNOF) a leader…
-
Valeo Pharma Announces Major Addition to its Senior Management Team
January 18, 2021 (Source) — Frederic Fasano named President and COO Steve Saviuk continues as CEO and becomes Vice-Chairman of…
-
XPhyto Announces Business Strategy and Milestones For 2021 Innovation to Impact
January 18, 2021 (Source) — Commercialization of rapid COVID-19 PCR test Clinical validation of transdermal and sublingual drug…
-
XPhyto Therapeutics Closes Fully Subscribed Private Placement
January 15, 2021 (Source) — XPhyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT) (“XPhyto” or the “Company”), has completed its previously announced and fully…
